Related Funds
Funds with similar focus
Fund Name | Location |
APOLLO INVEST | - |
Barikuta Partners | Bayern, Germany, Munich |
Bish Investments | - |
DNB | Norway, Oslo |
Future Positive Capital | France, Ile-de-France, Paris |
GreenCentre Canada | - |
Hughes | Germantown, Maryland, United States |
Lasa Kangwei Touzi | Chengguan District, China, Lhasa |
Maschhoff Family Foods | Carlyle, Illinois, United States |
Pavillion Capital | England, London, United Kingdom |
Plough Penny Partners | New York, New York, United States |
Premier Asset Management | Guildford, Surrey, United Kingdom |
Rongxing Venture Capital | Chengdu, China, Sichuan |
Scott Group Studio | - |
Suzhou Xinghuo Zhongda Industry Investment Fund | China, Jiangsu, Suzhou |
Venture Incubator, LLC | Jackson, Mississippi, United States |
Xueqiu Ziben | China, Hubei, Wuhan |
Notable deals
Company | Industry | Round Size | Date | Investors | Location |
TearClear | $22M | 11 Aug 2020 | Boston, Massachusetts, United States | ||
Tarsus Pharmaceuticals | $60M | 08 Jan 2020 | Irvine, California, United States | ||
CorneaGen | $37M | 10 Jul 2019 | Seattle, Washington, United States | ||
Oyster Point Pharmaceuticals | $93M | 26 Feb 2019 | San Francisco, California, United States | ||
$20M | 15 May 2018 | California, United States | |||
CorneaGen | $10M | 18 Oct 2016 | Seattle, Washington, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Latest deals
Company | Industry | Round Size | Date | Investors | Location |
TearClear | $22M | 11 Aug 2020 | Boston, Massachusetts, United States | ||
Tarsus Pharmaceuticals | $60M | 08 Jan 2020 | Irvine, California, United States | ||
CorneaGen | $37M | 10 Jul 2019 | Seattle, Washington, United States | ||
Oyster Point Pharmaceuticals | $93M | 26 Feb 2019 | San Francisco, California, United States | ||
$20M | 15 May 2018 | California, United States | |||
CorneaGen | $10M | 18 Oct 2016 | Seattle, Washington, United States |